All In Biotech

Drug Trial Radar · NCT04565574

A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy Participants

An Open-Label, Single-Dose Study to Assess the Effect of Food Intake and Drug-Drug Interactions of E7090 When Co-administered With Rabeprazole (Gastric Acid-Reducing Agent), or Rifampin (Strong CYP3A Inducer) in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Nov 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Oct 16, 2020

Primary completion

Mar 31, 2021

Study completion Mar 31, 2021

Sponsor

Lead sponsor
Eisai Co., Ltd.Eisai
Sponsor type
Industry
First posted
Sep 25, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will have three parts: Part A, Part B, and Part C. The primary purpose of Part A is to evaluate the effect of food on the rate and extent of E7090 absorption following single oral doses of E7090 in healthy participants, Part B is to evaluate the effects of rabeprazole (a gastric acid-reducing agent) on the rate and extent of E7090 absorption following single oral doses of E7090 in healthy participants, Part C is to evaluate the effects of rifampin (a strong Cytochrome P450 3A \[CYP3A\] inducer) on pharmacokinetics (PK) of single oral doses of E7090 in healthy participants.

Conditions

  • Healthy Participants

Interventions

  • E7090Drug

    Oral tablet.

  • Rabeprazole 20 mgDrug

    Rabeprazole 20 mg (2 tablets, each of 10 mg) oral tablet.

  • Rifampin 600 mgDrug

    Rifampin 600 mg (4 capsules, each of 150 mg) oral capsule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax: Maximum Observed Plasma Concentration of E7090Time frame: 0-144 hours post-dose following E7090 administration
  2. AUC(0-t): Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration of E7090Time frame: 0-144 hours post-dose following E7090 administration
  3. AUC(0-inf): Area Under the Concentration-time Curve From Zero (Pre-dose) Extrapolated to Infinite Time of E7090Time frame: 0-144 hours post-dose following E7090 administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Eisai trial site #1

    Minatoku, Tokoyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.